Emmanuel Dulac
Vorstandsvorsitzender bei Igyxos SA
Aktive Positionen von Emmanuel Dulac
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Igyxos SA
Igyxos SA Pharmaceuticals: MajorHealth Technology Igyxos SA engages in the development of an innovative medical and pharmaceutical technologies in the field of human fertility. It is involved in all phases of development, from the discovery of promising targets to the identification of potential lead compounds. The company was founded by Marie-Christine Maurel and is headquartered in Nouzilly, France. | Vorstandsvorsitzender | 01.06.2023 | - |
Karriereverlauf von Emmanuel Dulac
Ehemalige bekannte Positionen von Emmanuel Dulac
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ZEALAND PHARMA A/S | Vorstandsvorsitzender | 22.04.2019 | 30.03.2022 |
Präsident | 22.04.2019 | 30.03.2022 | |
SHIRE | Corporate Officer/Principal | 01.06.2014 | 01.08.2016 |
NOVARTIS AG | Corporate Officer/Principal | 01.02.2006 | 01.05.2014 |
SANOFI | Corporate Officer/Principal | 01.10.1994 | 01.08.2003 |
PROTEOSTASIS THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 05.02.2019 | - |
Independent Dir/Board Member | 05.02.2019 | - | |
ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 19.08.2016 | - |
Ausbildung von Emmanuel Dulac
ESSEC Business School | Masters Business Admin |
Statistik
International
Frankreich | 5 |
Vereinigte Staaten | 3 |
Dänemark | 2 |
Operativ
Corporate Officer/Principal | 4 |
Chief Executive Officer | 2 |
Masters Business Admin | 1 |
Sektoral
Health Technology | 8 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
ZEALAND PHARMA A/S | Health Technology |
NOVARTIS AG | Health Technology |
SANOFI | Health Technology |
Private Unternehmen | 4 |
---|---|
Université de Paris XI Paris Sud | Consumer Services |
Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Igyxos SA
Igyxos SA Pharmaceuticals: MajorHealth Technology Igyxos SA engages in the development of an innovative medical and pharmaceutical technologies in the field of human fertility. It is involved in all phases of development, from the discovery of promising targets to the identification of potential lead compounds. The company was founded by Marie-Christine Maurel and is headquartered in Nouzilly, France. | Health Technology |
- Börse
- Insiders
- Emmanuel Dulac
- Erfahrung